Trial Profile
A Phase 2, Randomized, Double-Blind, Multicenter, Dose-Ranging, Crossover Study to Evaluate the Safety and Efficacy of Subcutaneous Administration of CINRYZE® (C1 Esterase Inhibitor [Human]) With Recombinant Human Hyaluronidase (rHuPH20) for the Prevention of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Aug 2023
Price :
$35
*
At a glance
- Drugs Complement C1 inhibitor protein (Primary) ; Hyaluronidase
- Indications Angioedema; Hereditary angioedema
- Focus Therapeutic Use
- Sponsors Shire
- 24 Apr 2014 New trial record